{"nctId":"NCT00890409","briefTitle":"Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy","startDateStruct":{"date":"2002-05"},"conditions":["Hypoxic-Ischemic Encephalopathy"],"count":256,"armGroups":[{"label":"Normothermia","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Hypothermia","type":"EXPERIMENTAL","interventionNames":["Device: Cooling cap (YJW608-04B)"]}],"interventions":[{"name":"Cooling cap (YJW608-04B)","otherNames":["YJW608-04B"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age up to 6 hours\n* Gestational age ≥ 36 weeks and birth weight ≥ 2500 g\n* Apgar score ≤ 3 at 1 minute and ≤ 5 at 5 minutes, and/or cord blood gas pH \\< 7.0 or base deficit ≤ 16 mmol/L, and/or need for resuscitation or ventilation at 5 minutes of age\n* Clinical signs of encephalopathy (seizures, coma, abnormal muscle tone and irregular breathing, etc)\n\nExclusion Criteria:\n\n* Major congenital abnormalities\n* Infection\n* Other etiology of induced brain injury\n* Severe anemia (Hb \\< 120 g/L)\n\nEligible infants assessed for the severity of HIE according to criteria of the Neonatal Association of Chinese Academy of Pediatrics 25 modified from Sarnat and Sarnat 26 in 1986","healthyVolunteers":false,"sex":"ALL","maximumAge":"6 Hours","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Death","description":"The number of deaths by 18 months of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"Severe Neurodevelopmental Disability","description":"Severe disability was defined as cerebral palsy (CP) or mental retardation (MR). The definition of MR was development quotient (DQ) \\<70 by Gesell's Child Development Scale and CP was based on the Criteria of a level 3 to 5 by the Gross Motor Function Classification System (GMFCS).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Adverse Events","description":"Major adverse events were defined as severe arrhythmia (II or III degree A-V block or atrial or ventricular arrhythmia), major venous thrombosis, refractory hypotension (mean blood pressure less than 40 mmHg), moderate or severe scleredema (greater or equal to 20% body surface area), and severe bleeding.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}